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Background: NOD-like receptor, pyrin domain containing protein 3 (NLRP3) 
contributes to inflammation, cell death, and fibrosis in kidney disease. The 
NLRP3 inflammasome is activated by mitochondrial damage. However, it is 
unknown whether peroxisomal proliferator-γ coactivator-1α (PGC-1α), a key 
mitochondrial biogenesis regulator, can modulate NLRP3 inflammasome 
pathway. Here, I demonstrated that PGC-1α inhibits activation of NLRP3 
inflammasome via preserving mitochondrial viability during kidney injury. 
Methods: Primary renal tubular epithelial cells (RTECs) were isolated from 
C57BL/6 mice. The NLRP3 inflammasome pathway, mitochondrial dynamics 
and morphology, oxidative stress levels, and cell injury markers were examined 
in RTECs treated with TGF-β1 alone, TGF-β1+PGC-1α activators (metformin 
and 5-aminoimidazole-4-carboxamide ribonucleotide [AICAR]) or PGC-1α 
plasmid, and TGF-β1+small interfering-PGC-1α. For animal study, adenine-fed 
mice and unilateral ureteral obstruction (UUO) mice were treated with PGC-1α 
activator. 
Results: In vitro, TGF-β1 treatment to RTECs suppressed the expression levels 
of PGC-1α and mitochondrial dynamic-related genes. In addition, the NLRP3 
inflammasome pathway was activated and the expression levels of fibrotic and 
apoptotic cell death markers were increased. The indirect and direct expression 
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of PGC-1α with the activators and the plasmid improved mitochondrial dynamics 
and morphology and attenuated the NLRP3 inflammasome pathway and cell 
injury. In contrast, these changes were accentuated by PGC-1α knock-down. The 
oxidative stress levels, which are inducers of the NLRP3 inflammasome after 
mitochondrial damage, were increased and the expression of tumor necrosis 
factor α-induced protein 3 (TNFAIP3), which is regulated by PGC-1α and also 
known as a negative regulator of NLRP3 inflammasome, was decreased by TGF-
β1 and PGC-1α knock-down. However, restoration of PGC-1α significantly 
reversed these alterations. In vivo, adenine- and UUO-induced kidney injury 
models resulted in decreased expression levels of PGC-1α, TNFAIP3, and 
mitochondrial dynamics. In addition, the expression levels of oxidative stress, 
NLRP3 inflammasome pathway, and kidney fibrosis were increased in these mice. 
However, these changes were significantly reversed by treatment of PGC-1α 
activator. 
Conclusion: This study demonstrated that kidney injury was ameliorated by 
PGC-1α-induced inactivation of the NLRP3 inflammasome via modulation of 
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 Chronic kidney disease (CKD) is a global health problem and its prevalence has 
been rapidly increasing worldwide.1-3 Patients with CKD have an increased risk 
for progression to end-stage renal disease (ESRD) and mortality.4,5 It is therefore 
important to find effective therapeutic targets to prevent the progression of CKD.  
Renal tubulointerstitial inflammation and fibrosis are key pathological 
hallmarks in progression of CKD.6,7 These features are universal in failing 
kidneys and correlate strongly with renal function decline. Renal tubular 
epithelial cells (RTECs) account for 90% of the kidney mass and are fundamental 
to maintain fluid and electrolyte balance. RTECs have high baseline metabolic 
demands and mainly rely on adenosine triphosphate (ATP) via mitochondrial 
oxidative phosphorylation in energy generation.8 Renal tubules, thus, harbor 
abundant mitochondria and consume a high amount of energy for reabsorption as 
well as excretion. Therefore, RTECs have high levels of peroxisomal proliferator-
activated receptor-α (PPARα), peroxisomal proliferator-γ coactivator-1α (PGC-
1α), and a dense mitochondrial network to support their metabolic and functional 
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needs.9 In fact, a number of studies have suggested that mitochondrial 
dysfunction play a key role in kidney injury.8 
 NOD-like receptor family, pyrin domain-containing 3 (NLRP3) is involved in 
various host innate immune responses to microbial and nonmicrobial stimuli.10,11 
Several pathogens and endogenous danger signals released from damaged and 
dying cells including reactive oxygen species (ROS), extracellular ATP, 
monosodium urate crystals, nucleic acids, and extracellular matrix components 
activate the NLRP3 and lead to form a protein complex termed 
“inflammasome”.12 Upon activation, the NLRP3 proteins oligomerize and recruit 
the adaptor protein, apoptosis-associated speck-like protein containing a caspase 
recruitment domain (ASC), and the protease caspase-1 to form the inflammasome 
complex. The NLRP3 inflammasome then induces auto-process and activation of 
caspase-1, which results in cleavage of pro-cytokines to mature IL-1β and IL-18. 
Recently, the NLRP3 inflammasome has been implicated in the pathogenesis of 
kidney inflammation and fibrosis.13-15 In various animal models of kidney disease, 
NLRP3 inflammasome pathway is activated and its final products, IL-1β and IL-
18, can cause kidney tubule injury.14-17 Conversely, blocking this pathway 
attenuates kidney fibrosis.18 Interestingly, renal intrinsic cells such as TECs and 
podocytes express NLRP3, suggesting the potential role of NLRP3 
inflammasome signaling on cellular injury.19,20 
 Growing evidence suggests that mitochondrial dysfunction, characterized by a 
decline in number and the depolarization, swelling, and disruption of cristae, 
greatly contributes to kidney fibrosis.8 Damaged mitochondria do not efficiently 
produce ATP and release excessive ROS and mitochondrial DNA (mtDNA), 
which consequently trigger downstream inflammatory responses and lead to cell 
death and tubular injury. Moreover, recent studies have demonstrated the 
potential interaction between mitochondrial dysfunction and NLRP3 
inflammasome activation in renal tubular injury models.21-23 However, it is 
unknown whether PGC-1α, a key mitochondrial biogenesis regulator, can 
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regulate NLRP3 pathway via modulating mitochondrial dynamics. 
  Thus, I investigated the role of PGC-1α in the regulation of the NLRP3 
inflammasome activation in RTECs. In particular, I examined whether altered 
mitochondrial viability and dynamics induced by activation or suppression of 
PGC-1α can regulate NLRP3 inflammasome pathway, and thus affect kidney 
injury. 
 
II. MATERIALS AND METHODS 
 
1. Primary cell cultures  
RTECs were isolated from C57BL/6 mice. The cells were cultured in the 
Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA) containing 10% fetal bovine serum (FBS) (Gibco, Thermo 
Fisher Scientific, Waltham, MA, USA), 100 U/ml penicillin G (Sigma-Aldrich, 
UK), 2.5 mg/ml amphotericin B (Sigma-Aldrich, UK), and 20 ng/ml epidermal 
growth factor (EGF) (Sigma-Aldrich, UK). In short, kidneys were dissected, 
placed in 1 ml ice-cold Dulbecco's Phosphate-Buffered Saline (DPBS) (Gibco, 
Thermo Fisher Scientific, Waltham, MA, USA), and minced into pieces of 
approximately 1 mm3. These pieces were transferred and digested for 60 minutes 
at 37°C, and the supernatants were sieved through a 100-mm nylon mesh. After 
centrifugation for 10 minutes at 3000 rpm, the pellet was resuspended in sterile 
red blood cell lysis buffer (8.26 g NH4Cl, 1 g KHCO3, and 0.037 g EDTA per 1 
L double distilled H2O) and seeded in 10 cm culture dishes.  
 
2. Treatment of TGF-β1 and PGC-1α activators, and transfections to 
primary RTECs 
Subconfluent RTECs were FBS-restricted for 24 hours, and then the medium 
was replaced with 1% FBS DMEM medium for the control group and the same 
medium with TGF-β1 (5 ng/ml) (R&D systems, Minneapolis, MN, USA) for the 
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TGF-β1 group. RTECs were harvested for RNA and protein analyses at 48 hours 
after media changes. PGC-1α activators, metformin (10 mM) and 5-
aminoimidazole-4-carboxamide ribonucleotide (AICAR, 1 mM), were treated for 
both control and TGF-β1 groups. Both groups were also transfected with PGC-
1α plasmid (1 μg) (Addgene, Cambridge, MA, USA) and PGC-1α small 
interfering RNA (siRNA), using Lipofectamine 2000 and Plus reagents 
(Invitrogen, Carlsbad, CA, USA). Next, 6 hours after transfection, media were 
changed to serum-free media, and the cells were incubated for an additional 48 
hours. 
 
3. Animal study and treatment  
Male C57BL/6 mice (6 weeks old, initial weight 20 g) were purchased from The 
Jackson Laboratory (Bar Harbor, ME, USA). The animals were maintained in a 
temperature–controlled room (22°C) in a 12 hours light/dark cycle. One week 
after arrival, animals were divided into two groups and fed with either normal 
diet (ND; n = 10) or 0.2% adenine diet (AD; n = 10) for up to 4 weeks. Both ND 
and AD groups were also daily treated with intraperitoneal injection of PGC-1α 
activating drug, metformin (250 mg/kg), at one week before diet start. After 4 
weeks of ND or AD, animals were sacrificed and the kidneys were extracted 
while anesthetized with Zoletil (10 mg/kg) (Virbac, Carros, France). Unilateral 
ureter obstruction (UUO) was performed as described previously.24 In short, mice 
were anesthetized with Zoletil (10 mg/kg) (Virbac, Carros, France) and the left 
ureter was exposed via an incision under 0.5 cm from costal margin. The mid-
ureter was then obstructed using a ligation with silk sutures. The sham-operated 
mice underwent the same procedure without the obstruction of the ureter and used 
as controls. Both sham and UUO mice were daily treated with intraperitoneal 
injection of metformin (250 mg/kg) and AICAR (500 mg/kg). Mice were 
sacrificed at 5 days after UUO and the kidneys were removed while anesthetized.  
Kidney samples were then immediately frozen in liquid nitrogen and stored at -
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80°C until use. The protocols for animal experiments were approved by the 
Committee for the Care and Use of Laboratory Animals at Yonsei University 
College of Medicine in Seoul, Republic of Korea (No. H14C2003). All 
experiments with animals were conducted in accordance with the Principles of 
Laboratory Animal Care (NIH Publication no. 85–23, revised 1985). 
 
4. Total RNA extraction  
Whole kidney samples were rapidly frozen using liquid nitrogen and 
homogenized by mortar and pestle thrice with 700 μl of RNAiso reagent (Takara 
Bio Inc., Otsu, Shiga, Japan). For RTECs, 700 μl of RNAiso were added to the 
cell culture dish, and the suspension was collected and homogenized for 5 
minutes at room temperature (RT). After then, 160 μl of chloroform was added 
into the homogenized samples of the kidneys and cells. Next, the mixture was 
shaken vigorously for 30 seconds, stored for 3 minutes at RT, and centrifuged 
12,000 rpm for 15 minutes at 4°C. The aqueous phase located in the top of three 
phases was transferred to a fresh tube carefully not to be contaminated with the 
other phases. Extracted RNA was precipitated by adding 400 μl of isopropanol, 
and centrifuged at 12,000 rpm for 30 minutes at 4°C. The RNA pellet was washed 
with 70% ethanol, air-dried for 2 minutes, and dissolved in sterile diethyl 
pyrocarbonate (DEPC)-treated distilled water. The quantity and quality of 
extracted RNA were assessed by spectrophotometric measurements at 
wavelengths of 260 and 280 nm. 
 
5. Reverse transcription 
A Takara cDNA synthesis kit (Takara Bio Inc., Otsu, Shiga, Japan) was used to 
obtain first strand cDNA. Reverse transcription was conducted using 2 μg of total 
RNA extracts with 10 μM random hexanucleotide primer, 1 mM dNTP, 8 mM 
MgCl2, 30 mM KCl, 50 mM Tris-HCl at pH 8.5, 0.2 mM dithiothreithol, 25 U 
RNase inhibitor, and 40 U PrimeScript reverse transcriptase. The mixture was 
incubated for 10 minutes at 30°C, and for 1 hour at 42°C, followed by incubation 
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for 5 minutes at 99°C for the inactivation of the enzyme. 
 
6. Real–time quantitative polymerase chain reaction 
 
The RNAs used for amplification were 25 ng per reaction tube. Using the ABI 
PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, 
USA), a total volume of 20 μl mixture in each well was used containing 10 μl of 
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 5 
μl of cDNA, and 5 pmol sense and antisense primers. The primer concentrations 
were determined by preliminary experiments that analyzed the optimal 
concentrations of each primer. The quantitative polymerase chain reaction (qPCR) 
conditions were as follows: 35 cycles of denaturation for 30 minutes at 94.5°C, 
annealing for 30 seconds at 60°C, and extension for 1 minute at 72°C. Initial 
heating for 9 minutes at 95°C and final extension for 7 minutes at 72°C were 
performed for all PCR reactions. The primer sequences used in this study were 
described in Table 1. Each sample was run in triplicate in separated tubes and a 
control without cDNA was also run in parallel with each assay. After real-time 
PCR, the temperature was increased from 60 to 95°C at a rate of 2°C/minute to 
construct a melting curve. The cDNA content of each specimen was determined 
using a comparative CT method with 2-△△CT. The results were given as the relative 
expression normalized to the expression of 18s ribosomal RNA (rRNA) and 
expressed in arbitrary units. 
 
Table 1. Sequences of oligonucleotide primers used for qPCR test 

















































7. Western blot analyses 
Protein expression levels of the NLRP3 inflammasome pathway, oxidative 
stress marker, and profibrotic markers were examined with Western blot analyses. 
Harvested cultured cells and the mouse kidneys were lysed in sodium dodecyl 
sulfate (SDS) sample buffer [2% SDS, 10 mM Tris-HCl, pH 6.8, 10% (vol/vol) 
glycerol]. Lysate was centrifuged at 10,000 g for 10 minutes at 4°C, and the 
supernatant was stored at -70°C. Protein concentrations were determined with a 
Bio-Rad kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Laemmli sample 
buffer was added to aliquots of 50 μg of the protein extracts, which were heated 
for 5 minutes at 100°C and electrophoresed in acrylamide denaturating SDS-
polyacrylamide gel. A Hybond-ECL membrane was used to transfer protein using 
a Hoeffer semidry blotting apparatus (Hoeffer Instruments, San Francisco, CA, 
USA). After the protein was transferred to the membrane, it was incubated in 
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blocking buffer A (PBS, 0.1% Tween-20, and 5% nonfat milk) for 1 hour at RT, 
and then incubated overnight at 4°C in a 1:1,000 dilution of following polyclonal 
antibodies; PGC-1α (Abcam, Cambridge, MA, USA), NLRP3 (Adipogen Life 
Sciences, CA, USA), ASC (Cell Signaling Technology, MA, USA), IL-1β 
(Abcam, Cambridge, MA, USA), IL-18 (Abcam, Cambridge, MA, USA), tumor 
necrosis factor α induced protein 3, (TNFAIP3) (Cell Signaling Technology, MA, 
USA), fibronectin (DAKO, Carpentaria, CA, USA), type I collagen (Southern 
Biotech, Birmingham, AL, USA), Bax (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), B cell lymphoma–2 (Bcl–2) (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), Caspase-3 (Cell Signaling Technology, MA, USA), and β–actin 
(Sigma–Aldrich, UK). A horseradish peroxidase (HRP)–conjugated anti–rabbit 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti–mouse IgG antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as secondary 
antibodies. After frequent rinses, the membranes were developed by 
chemiluminescence (Gibco, Thermo Fisher Scientific, Waltham, MA, USA). To 
quantify the band densities, Image J software (National Institutes of Health, 
Bethesda, MD; online at http://rsbweb.nih.gov/ij) was used. The changes in the 
optical densities of bands from the treated groups relative to control cells or 
tissues were used for analysis. 
 
8. Assay of NLRP3 inflammasome assembly 
To determine the oligomerization of ASC, a disuccinimidyl suberate (DSS) 
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA)-mediated cross-linking 
assay was performed as described previously.25 In brief, kidney tissue samples 
were mixed in 1 ml of OPTI-MEM I medium for 2 hours in the absence or 
presence of AD. The samples were pelleted by centrifugation and lysed in 0.5 ml 
of ice-cold buffer A. The lysates were centrifuged at 6000 rpm at 4°C for 10 
minutes. The pellets were washed twice with PBS and then resuspended in 500 
µl PBS. The re-suspended pellets were cross-linked with fresh DSS (2 mM) for 
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30 minutes, and then pelleted by centrifugation at 6000 rpm for 10 minutes. The 
cross-linked pellets were resuspended in 30 µl SDS sample buffer and 
fractionated on 12% SDS polyacrylamide gel followed by immunoblotting with 
ASC antibody (Cell Signaling Technology, MA, USA).  
 
9. Measurement of oxidative stress levels 
Oxidative stress (malondialdehyde [MDA]) levels were measured in RTECs and 
kidney tissues using an MDA assay kit (Abcam, Cambridge, MA, USA). Ten mg 
of RTECs were homogenized on ice in 300 μl of MDA lysis buffer (Abcam, 
Cambridge, MA, USA), then centrifuged (13,000×g, 10 minutes) to remove 
insoluble materials. Ten ml of plasma were mixed with 500 μl of 42 mM H2SO4 
and 125 μl of phosphotungstic acid solution at RT for 5 minutes. After 
centrifuging (13,000×g, 3 minutes), the pellet was re-suspended on ice with 100 
μl of double-distilled H2O. Then, 200 μl of solution and 600 μl of 2-thiobarbituric 
acid solution were incubated at 95°C for 60 minutes before cooling to RT in the 
ice bath for 10 minutes. The intensity of absorbance at 532 nm was proportional 
to the MDA level. To measure mitochondrial ROS production, cells were 
resuspended in Hank’s Balanced Salt Solution after appropriate treatments, and 
stained with MitoSOX (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) 
at 37°C for 20 minutes.  
 
10. Isolation of mitochondria 
RTECs were fractionated into cytosol and mitochondria by using Mitochondria 
isolation kit (BioVision, Inc. CA, USA) as per the manufacturer’s protocol.26 In 
short, cells were collected and washed with 10 ml ice cold PBS. Cells were 
centrifuged at 600×g for 5 minutes at 4°C and resuspended in 1.0 ml of 1X 
Cytosol Extraction Buffer. Homogenization was performed on ice and 
centrifuged at 1,200×g for 10 minutes at 4°C to remove nuclei and intact cells. 
The collected supernatant was centrifuged at 10,000×g for 30 minutes at 4°C. The 
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resulting pellets were resuspended in 1.0 ml of 1X Cytosol Extraction Buffer and 
centrifuged at 10,000×g for 30 minutes at 4ºC to obtain mitochondria. The 
obtained mitochondria were lysed in 30 μl of Mitochondrial Lysis Buffer and 
added to 100ul Enzyme B Mix with 100 μl absolute ethanol. After centrifugation, 
resulting pellet was mtDNA. The cytosolic mtDNA was obtained from the 
supernatant after precipitation with ethanol. The concentration of mtDNA was 
determined by qPCR assay.  
 
11. Electron microscopic examination 
I next examined mitochondrial structure by standard transmission electron 
microscopy. Primary RTECs were fixed with a mixture of 2% paraformaldehyde 
and 2.5% glutaraldehyde overnight, washed, dehydrated, and embedded in a resin 
according to standard procedures. Mitochondria were examined under a JEOL 
1011 microscope (JEOL, Tokyo, Japan). 
 
12. Histological and Immunofluorescent staining 
To evaluate histologic features, formalin-fixed, paraffin-embedded kidney 
sections were stained with Masson’s trichrome reagent. All slide pictures were 
captured using an Olympus DP73 microscope.  
For immunofluorescent staining for mitochondria, MitoTracker Deep Red 
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA) was used. RTECs were 
fixed in 4% paraformaldehyde and blocked in DPBS containing 5% normal rabbit 
serum and 0.1% Tween-20. Cells were then stained with anti-mouse NLRP3, 
MitoTracker, followed by AlexaFluor594-conjugated goat anti-rabbit antibodies 
(Jackson ImmunoResearch, West Grove, PA), and finally slides were mounted 
with DAPI and imaged.  
 
13. Enzyme-linked immunosorbent assay  
Levels of IL-1β and IL-18 in RTECs and the kidney tissues were determined 
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using commercial enzyme-linked immunosorbent assay (ELISA) kits (R&D 
Systems, Minneapolis, MN, USA).  
 
14. Statistical analyses 
Statistical analyses were performed using IBM SPSS software for Windows 
version 23.0 (IBM Corporation, Armonk, NY, USA). Continuous variables are 
presented as mean ± standard deviation, and categorical variables are shown as 
numbers (percentage). To analyze differences between two groups, Mann–
Whitney U test was used, and Kruskal–Wallis test was applied for comparison 
between more than two groups. For all analyses, P < 0.05 was considered 
statistically significant. 
 
III. RESULTS  
 
1. The alterations in PGC-1α, mitochondrial dynamics, and NLRP3 
inflammasome pathway in TGF-β1-treated RTECs 
First, I examined the expression of PGC-1α, mitochondrial dynamics, and 
NLRP3 pathway in RTECs treated with TGF-β1. In these cells, TGF-β1 treatment 
decreased the transcript and protein levels of PGC-1α (Fig. 1A and B). 
Accordingly, mRNA expression levels of mitofusin (Mfn), a mitochondrial 
fusion-related gene, and mitochondrial transcription factor A (Tfam), which 
represents mitochondrial mass, were significantly decreased, whereas that of 
dynamin-related protein 1 (Drp1), a mitochondrial fission-related gene, was 
increased compared with control (Fig. 1C-E). In addition, TGF-β1 treatment 
activated NLRP3 inflammasome signaling evidenced by increased expression 
levels of NLRP3 inflammasome pathway-related genes and proteins (Fig. 2A-E). 
Furthermore, expression levels of fibrotic markers including fibronectin and 
collagen 1, and apoptotic cell death index of Bax/bcl-2 ratio and cleaved-caspase 




Figure 1. Changes in PGC-1α expression and mitochondrial dynamics in 
TGF-β1-treated RTECs. (A) mRNA and (B) protein expression levels of PGC-
1α were decreased in TGF-β1-treated RTECs. (C-E) mRNA expression of 
mitochondrial dynamic-related genes including Mfn, Tfam, and Drp1were altered 
in TGF-β1-treated RTECs.  
Note: * P<0.05 vs. control.  
Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; RTEC, 
renal tubular epithelial cell; Mfn, mitofusin; Tfam, mitochondrial transcriptional 




Figure 2. Changes in NLRP3 inflammasome pathway and cell injury in 
TGF-β1-treated RTECs. (A-D) mRNA and (E) protein expression levels of 
NLRP3 inflammasome pathway were increased in TGF-β1-treated RTECs. (F-
H) mRNA and (I) protein expression levels of fibrotic markers including 
fibronectin and collagen 1, and apoptotic cell death markers of Bax/bcl-2 and 
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cleaved caspase-3 were increased in TGF-β1-treated RTECs.  
Note: * P<0.05 vs. control. 
Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; NLRP3, 




2. PGC-1α restores mitochondrial dynamics and morphology and 
attenuates the NLRP3 inflammasome activation and cell injury  
 PGC-1α is a key regulator of mitochondria biogenesis. Thus, I then evaluated 
whether PGC-1α could attenuate cell injury by suppressing NLRP3 inflammation 
pathway. To this end, I first used indirect activators of PGC-1α including 
metformin and AICAR. These PGC-1α activators restored the altered expression 
of PGC-1α (Fig. 3A and B) and mitochondrial dynamic-related genes and 
mitochondrial mass caused by TGF-β1 in RTECs (Fig. 3C-E). Moreover, the 
increased expression levels of NLRP3 inflammasome pathway (Fig. 4A-F), 
fibrotic markers, and apoptotic cell death index in TGF-β1-treated cells were 
concomitantly decreased by PGC-1α activators (Fig. 4G-J). Accordingly, 
additional experiments with direct overexpression using PGC-1α plasmid 
restored the decreased expression of PGC-1α and mitochondrial dynamic-related 
genes and mitochondrial mass caused by TGF-β1 in RTECs (Fig. 5A-B). The 
increased expression levels of NLRP3 inflammasome pathway, fibrotic markers, 
and apoptotic cell death index in TGF-β1-treated cells were attenuated by direct 
overexpression of PGC-1α (Fig. 6A-J). These findings were corroborated by 
additional experiments with direct overexpression using PGC-1α plasmid (Fig. 
5A-D and Fig. 6A-J). To substantiate these findings, I further examined 
mitochondrial morphological changes by MitoTracker Red staining (Fig. 7A). 
TGF-β1 decreased the staining intensity of MitoTracker and these were restored 
by PGC-1α overexpression. Conversely, the increased expression of NLRP3 in 
TGF-β1-treated RTECs was reduced by PGC-1α overexpression. The mtDNA 
copy numbers were decreased in mitochondrial fraction and increased in 
cytosolic fraction after TGF-β1 treatment, suggesting that mtDNA was released 
from mitochondria into cytosol. However, these changes were restored after 




Figure 3. PGC-1α activators restore mitochondrial dynamics and 
morphology in TGF-β1-treated RTECs. (A) mRNA and (B) protein expression 
levels of PGC-1α were restored in TGF-β1-treated RTECs with PGC-1α 
activators. (C-E) mRNA expression levels of mitochondrial dynamic-related 
genes were restored in TGF-β1-treated RTECs with PGC-1α activators. 
Note: * P<0.05 vs. control; # P<0.05 vs. TGF-β1-treated RTECs. 
Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; RTEC, 
renal tubular epithelial cell; Met, metformin; AICAR, 5-aminoimidazole-4-
carboxamide ribonucleotide; Mfn, mitofusin; Tfam, mitochondrial 




Figure 4. PGC-1α activators attenuate the NLRP3 inflammasome activation 
and cell injury. (A-D) mRNA and (E) protein expression levels of NLRP3 
inflammasome pathway and (F) concentrations of IL-1β and IL-18 assessed by 
ELISA were reduced in TGF-β1-treated RTECs with PGC-1α activators. (G-I) 
mRNA and (J) protein expression levels of fibrotic and apoptotic markers were 
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attenuated in TGF-β1-treated RTECs with PGC-1α activators.  
Note: * P<0.05 vs. control; # P<0.05 vs. TGF-β1-treated RTECs. 
Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; NLRP3, 
NOD-like receptor family, pyrin domain-containing 3; ELISA, enzyme-linked 




Figure 5. Direct overexpression of PGC-1α restores mitochondrial dynamics 
and morphology. (A) protein expression level of PGC-1α was restored in TGF-
β1-treated RTECs after transfection of PGC-1α plasmid. (B-D) mRNA 
expression levels of mitochondrial dynamic-related genes in TGF-β1-treated 
RTECs revealed trends of restoration after transfection of PGC-1α plasmid. 
Note: *, # P<0.05 vs. control; † P<0.05 vs. TGF-β1-treated RTECs. 
Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; RTEC, 
renal tubular epithelial cell; Mfn, mitofusin; Tfam, mitochondrial transcriptional 




Figure 6. Direct overexpression of PGC-1α attenuates the NLRP3 
inflammasome activation and cell injury. (A-D) mRNA and (E) protein 
expression levels of NLRP3 inflammasome pathway and (F) concentrations of 
IL-1β and IL-18 assessed by ELISA were reduced in TGF-β1-treated RTECs with 
transfection of PGC-1α plasmid. (G-I) mRNA and (J) protein expression levels 
of fibrotic and apoptotic markers were attenuated in TGF-β1-treated RTECs with 
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transfection of PGC-1α plasmid. 
Note: *, # P<0.05 vs. control; † P<0.05 vs. TGF-β1-treated RTECs. 
Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; NLRP3, 
NOD-like receptor family, pyrin domain-containing 3; ELISA, enzyme-linked 





Figure 7. Localization of NLRP3 with mitochondria and assessment of 
mtDNA counts in TGF-β1-treated RTECs with or without PGC-1α 
overexpression. (A) Confocal microscopy with Immunofluorescent staining 
revealed co-localization of NLRP3 (green) with the destructed mitochondria (red) 
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in TGF-β1-treated RTECs, which were restored by PGC-1α overexpression. The 
blue signal represents nuclear fluorescence. (B) MtDNA copy numbers were 
decreased in mitochondrial fraction, while increased in cytosolic fraction in TGF-
β1-treated RTECs, which were reversed by PGC-1α overexpression.  
Note: * P<0.05 vs. control; # P<0.05 vs. TGF-β1-treated RTECs. 
Abbreviations: NLRP3, NOD-like receptor family, pyrin domain-containing 3; 
mtDNA, mitochondrial DNA; RTEC, renal tubular epithelial cell; PGC-1α, 




3. PGC-1α deficiency results in activation of NLRP3 inflammasome and 
worsens cell injury  
To further clarify the mechanistic link between PGC-1α and NLRP3 
inflammasome pathway, I conversely knocked down PGC-1α gene. PGC-1α gene 
was effectively silenced by siRNA against Ppargc1α (siPGC-1α) (Fig. 8A and 
B). PGC-1α deficiency decreased the expression of Mfn and Tfam, but increased 
the expression of Drp1 (Fig. 8C-E). These changes were further exacerbated in 
TGF-β1-treated cells with PGC-1α knock-down. In accordance with these, the 
expression of NLRP3, IL-1β, and IL-18 were more increased in these dual 
treatment cells (Fig. 9A-E). The concentrations of IL-1β and IL-18 were further 
elevated after treatment of siPGC-1α measured by ELISA (Fig. 9F). Furthermore, 
PGC-1α knock-down together with TGF-β1 worsened cell injury evidenced by 




Figure 8. Downregulation of PGC-1α gene increases mitochondrial damage. 
(A) mRNA and (B) protein expression levels of PGC-1α were downregulated in 
TGF-β1-treated RTECs with siPGC-1α. (C-E) mRNA expression levels of 
mitochondrial dynamic-related genes were dysregulated in TGF-β1-treated 
RTECs with siPGC-1α.  
Note: * P<0.05 vs. control; # P<0.05 vs. TGF-β1-treated RTEC. 
Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; RTEC, 
renal tubular epithelial cell; Met, metformin; siRNA, small interfering RNA; Mfn, 





Figure 9. Downregulation of PGC-1α gene exacerbates cell injury with 
activation of NLRP3 inflammasome. (A-D) mRNA and (E) protein expression 
levels of NLRP3 inflammasome pathway and (F) concentrations of IL-1β and IL-
18 assessed by ELISA were increased in TGF-β1-treated RTECs with siPGC-1α. 
(G-I) mRNA and (J) protein expression levels of fibrotic and apoptotic markers 
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were enhanced in TGF-β1-treated RTECs with siPGC-1α. 
Note: * P<0.05 vs. control; # P<0.05 vs. TGF-β1-treated RTEC. 
Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; NLRP3, 
NOD-like receptor family, pyrin domain-containing 3; RTEC, renal tubular 
epithelial cell; Met, metformin; siRNA, small interfering RNA. 
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4. Dysregulated mitochondria-induced oxidative stress and PGC-
1α/TNFAIP3 axis regulate NLRP3 inflammasome 
Because oxidative stress is a positive regulator of NLRP3 inflammasome and its 
level is increased upon mitochondrial damage, I examined markers of oxidative 
stress in TGF-β1-treated cells with or without PGC-1α. TGF-β1 increased 
MitoSOX staining intensity and MDA levels in RTECs and PGC-1α activators 
and direct PGC-1α overexpression attenuated this overproduction of 
mitochondrial ROS (Fig. 10A). Conversely, PGC-1α knock-down further 
increased MDA levels in TGF-β1-treated RTECs (Fig. 10B). Then, I further 
examined TNFAIP3, which is regulated by PGC-1α and also known as a negative 
regulator of NLRP3 inflammasome. TGF-β1 reduced transcript levels of Tnfaip3 
and this decreased expression of Tnfaip3 was restored by restoration of PGC-1α. 
Conversely, PGC-1α knock-down resulted in further decreased expression of 
Tnfaip3 (Fig. 10C). These findings suggest that PGC-1α can regulate NLRP3 




Figure 10. Dysregulated mitochondria-induced oxidative stress and PGC-
1α/TNFAIP3 axis regulate NLRP3 inflammasome. (A) Confocal microscopy 
analysis with MitoSOX staining revealed increased production of mitochondria-
generated ROS in TGF-β1-treated RTECs, which were reduced with PGC-1α 
activators and transfection of PGC-1α plasmid. (B) Measurement of oxidative 
stress levels by MDA showed reduction of oxidative stress levels in TGF-β1-
treated RTECs with PGC-1α activators and transfection of PGC-1α plasmid, 
which were increased by siPGC-1α. (C) mRNA expression level of TNFAIP3 in 
TGF-β1-treated RTECs was increased with PGC-1α activators and transfection 
of PGC-1α plasmid, which were reduced by siPGC-1α. 
Note: * P<0.05 vs. control; # P<0.05 vs. TGF-β-treated RTECs. 
Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; ROS, 
reactive oxygen species; RTEC; renal tubular epithelial cell; TNFAIP3, tumor 
necrosis factor α induced protein 3; NLRP3, NOD-like receptor family, pyrin 
domain-containing 3; MDA, malondialdehyde; Met, metformin; AICAR, 5-
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aminoimidazole-4-carboxamide ribonucleotide; siRNA, small interfering RNA. 
  
5. PGC-1α protects kidney fibrosis and attenuates mitochondrial damage 
and activation of NLRP3 inflammasome in adenine-fed animal model 
To confirm the findings of in vitro study, I tested the effects of metformin, a 
PGC1α activator, using adenine-induced kidney injury model. In the kidney of 
adenine-fed mice, expression level of TGF-β1 was increased, while that of PGC-
1α was decreased (Fig. 11A and B). In addition, there were altered expression of 
mitochondria dynamic-related genes in these mice; the decreased expression 
levels of Mfn and Tfam and the increased expression of Drp1 (Fig. 11C-E). 
Treatment with metformin, restored the decreased expression of PGC-1α and 
reversed the altered expression of mitochondrial dynamic-related genes in 
adenine-fed mice (Fig. 11A-E). Electron microscopy examination also confirmed 
the loss of mitochondria integrity in TECs of adenine-fed mice. These were 
significantly improved by PGC-1α activator (Fig. 11F). Moreover, the increased 
expression levels of NLRP3 inflammasome pathway components were 
concomitantly decreased by PGC-1α activator (Fig. 12A-E). The concentrations 
of IL-1β and IL-18, the final products of NLRP3 pathway, were significantly 
decreased by metformin treatment (Fig. 12F). 
Oligomerization of NLRP3 with the adapter protein, ASC, is a key step of 
inflammasome complex formation. Thus, I examined whether the assembly of 
NLRP3 inflammasome is affected by PGC-1α in animal model. In adenine-fed 
mice, NLRP3 oligomerization and activation was confirmed by ASC binding to 
NLRP3 and this was abolished by PGC-1α activator (Fig. 12G). In aggregates, 
these findings indicate that the assembly of NLRP3 inflammasome complex was 
induced during kidney injury, and the activation of this pathway was attenuated 





Figure 11. PGC-1α activator protects mitochondrial damage in adenine-fed 
animal model. (A) mRNA and (B) protein expression levels of PGC-1α in 
adenine-fed mice were increased with PGC-1α activator. (C-E) mRNA 
expression levels of mitochondrial dynamic-related genes were restored in 
adenine-fed mice with PGC-1α activator. (F) Transmission electron microscopy 
images of RTECs from adenine-fed mice showed restoration of mitochondrial 
structures with PGC-1α activator. 
Note: * P<0.05 vs. control; # P<0.05 vs. Adenine. 
Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; NLRP3, 
NOD-like receptor family, pyrin domain-containing 3; Ade, adenine; Met, 
metformin; Mfn, mitofusin; Tfam, mitochondrial transcriptional factor A; Drp1, 




Figure 12. PGC-1α activator protects cell injury and attenuates 
oligomerization and activation of NLRP3 inflammasome in adenine-fed 
animal model. (A-D) mRNA and (E) protein expression levels of NLRP3 
inflammasome pathway in adenine-fed mice were reduced with PGC-1α activator. 
(F) Concentration of IL-1β and IL-18 in kidney tissues measured by ELISA were 
decreased in adenine-fed mice with PGC-1α activator. (G) ASC oligomeric 
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structures assayed by DSS-mediated cross-linking were observed in adenine-fed 
mice, which were attenuated with PGC-1α activator.  
Note: * P<0.05 vs. control; # P<0.05 vs. Adenine. 
Abbreviations: PGC-1α, peroxisomal proliferator–γ coactivator-1α; NLRP3, 
NOD-like receptor family, pyrin domain-containing 3; ASC, apoptosis-
associated speck-like protein containing a caspase recruitment domain; Ade, 
adenine; Met, metformin; ELISA, enzyme-linked immunosorbent assay; DSS, 
disuccinimidyl suberate. 
 
6. PGC-1α activator regulates TNFAIP3 associated NLRP3 inflammasome 
activation with oxidative stress and protects kidney fibrosis in adenine-fed 
animal model 
Similar to the findings of in vitro study, MDA levels were significantly 
increased in adenine-fed mice. The enhanced oxidative stress was largely reduced 
by PGC-1α activator (Fig. 13A). In contrast, there was a decreased expression of 
TNFAIP3 in adenine-fed mice and PGC-1α activator restored this expression 
(Fig. 13B and C). In accordance with these findings, the expression levels of 
fibrotic markers and apoptotic cell death index were significantly increased in 
these mice. In contrast, PGC-1α activator reversed all these findings (Fig. 14A-
D). Together with these findings, the degree of kidney fibrosis was also reduced 
after treatment of metformin to adenine-fed mice (Fig. 14E). 
36 
 
   
Figure 13. PGC-1α activator regulates TNFAIP3 associated NLRP3 
inflammasome activation with oxidative stress in adenine-fed animal model. 
(A) The oxidative stress levels measured by MDA were reduced in adenine-fed 
mice with PGC-1α activator. (B) mRNA and protein (C) expression levels of 
TNFAIP3 were restored in adenine-fed mice with PGC-1α activator. 
Note: * P<0.05 vs. control; # P<0.05 vs. Adenine. 
Abbreviations: PGC-1α, peroxisomal proliferator–γ coactivator-1α; TNFAIP3, 
tumor necrosis factor α induced protein 3; NLRP3, NOD-like receptor family, 




Figure 14. PGC-1α activator protects kidney fibrosis in adenine-fed animal 
model.  
(A-C) mRNA and (D) protein expression levels of fibrotic and apoptotic markers 
were reduced in adenine-fed mice with PGC-1α activator. (E) Degree of kidney 
fibrosis by Masson’s trichrome staining were attenuated in adenine-fed mice with 
PGC-1α activator. 
Note: * P<0.05 vs. control; # P<0.05 vs. Adenine. 
Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; NLRP3, 




7. PGC-1α protects kidney fibrosis and attenuates mitochondrial damage 
and activation of NLRP3 inflammasome in UUO model 
To substantiate my findings, I additionally performed experimental study using 
different renal tubular injury model, unilateral ureteral obstruction (UUO) model. 
Similar to the findings in adenine-fed animal model above, I also observed the 
altered expression levels of PGC-1α and mitochondrial dynamic-related genes in 
UUO mice. In contrast, PGC-1α activators reversed all these findings (Fig. 15A-
E). Electron microscopy examination also confirmed the loss of mitochondria 
integrity in RTECs of UUO mice. These were significantly improved by PGC-1α 
activators (Fig. 15F). Moreover, the expression levels of NLRP3 inflammasome 
pathway and MDA levels were increased, whereas the expression of TNFAIP3 
was decreased in these mice (Fig. 16A-G). Along with these findings, fibrotic 
and apoptotic markers were also increased (Fig. 16H-K). However, PGC-1α 




Figure 15. PGC-1α activators attenuates mitochondrial damage in UUO 
animal model. (A) mRNA and (B) protein expression levels of PGC-1α were 
increased in UUO mice with PGC-1α activators. (C-E) mRNA expression levels 
of mitochondrial dynamic-related genes in UUO mice were restored with PGC-
1α activators. (F) Transmission electron microscopy images of RTECs from 
UUO mice showed restoration of mitochondrial structure with PGC-1α activators. 
Note: * P<0.05 vs. control; # P<0.05 vs. UUO. 
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Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; NLRP3, 
NOD-like receptor family, pyrin domain-containing 3; UUO, unilateral ureteral 
obstruction; Met, metformin; AICAR, 5-aminoimidazole-4-carboxamide 
ribonucleotide; Mfn, mitofusin; Drp1, dynamin related protein 1; Tfam, 





Figure 16. PGC-1α activator protects kidney fibrosis and attenuates 
activation of NLRP3 inflammasome in UUO animal model. (A-D) mRNA and 
(E) protein expression levels of NLRP3 inflammasome pathway in UUO mice 
were reduced with PGC-1α activator. (F) Decreased oxidative stress levels by 
MDA were observed in UUO mice with PGC-1α activator. (G) mRNA 
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expression level of TNFAIP3 in UUO was increased with PGC-1α activators. (H-
J) mRNA and (K) protein expression levels of fibrotic and apoptotic markers in 
UUO mice were reduced with PGC-1α activators.  
Note: * P<0.05 vs. control; # P<0.05 vs. UUO. 
Abbreviations: PGC-1α, peroxisomal proliferator-γ coactivator-1α; NLRP3, 
NOD-like receptor family, pyrin domain-containing 3; UUO, unilateral ureteral 
obstruction; Met, metformin; AICAR, 5-aminoimidazole-4-carboxamide 





Figure 17. Schematic summary. PGC-1α regulates the NLRP3 inflammasome 
activation via modulating mitochondrial viability and dynamics, and TNFAIP3 
during kidney cell death and fibrosis. 
Abbreviations: PGC-1α, peroxisomal proliferator–γ coactivator-1α; NLRP3, 
NOD-like receptor family, pyrin domain-containing 3 TNFAIP3, tumor necrosis 




The present study showed that PGC-1α decreased mitochondrial damage and 
oxidative stress levels, restored mitochondrial integrity and TNFAIP3, and 
attenuated the activation of NLRP3 inflammasome pathway in TGF-β-treated 
RTECs and animal models of kidney injury. These improvements concomitantly 
resulted in decreased cell injury and fibrosis. A schematic figure showing the 
potential mechanism on regulation of NLRP3 by PGC-1α is presented in Figure 
17. The findings of my study unravel the role of PGC-1α in the regulation of the 
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NLRP3 inflammasome signaling via modulating mitochondrial viability and 
dynamics and also suggest a possible therapeutic potential of PGC-1α during 
kidney injury.  
The NLRP3 inflammasome has been implicated in the pathogenesis of cellular 
injury, inflammation, and fibrosis in various kidney injury models.13-18,27,28 A 
previous study by Vilaysane et al. 13 showed that the expression levels of markers 
of inflammasome activation such as caspase-1, IL-1β, and IL-18 were increased 
in mice after UUO. Genetic deletion of Nlrp3 in these mice markedly decreased 
inflammation and tubular injury. Furthermore, these NLRP3 Inflammasome-
regulated cytokines such as IL-1β and IL-18 induced mesenchymal markers in 
RTECs in a dose dependent manner.17,29 In contrast, IL-18 neutralization 
substantially prevented renal tubular injury and fibrosis. Interestingly, in a cohort 
of renal biopsies from patients with kidney disease, the increased expression 
levels of NLRP3 well correlated with decreased renal function. In addition, 
markers of inflammasome signaling such as IL-18 and caspase-1 were expressed 
in human kidney disease,30 and circulating IL-18 levels were elevated in patients 
with CKD or nephrotic syndrome.31-33 These findings suggest that NLRP3 may 
play a role in human kidney disease. 
In agreement with previous studies, I showed that the expression levels of 
NLRP3 inflammasome pathways including NLRP3, ASC, IL-1β, and IL-18 were 
increased along with elevated expression levels of cellular injury markers during 
kidney injury in TGF-β1-treated RTECs and animal models with adenine-diet 
and UUO. Several damage-associated molecular patterns (DAMPs) released 
during renal tubular cell injury are suggested to activate the NLRP3 
inflammasome.34 These DAMPs include ROSs, extracellular ATP, uric acid, 
nucleic acids, and extracellular matrix components such as hyaluronan and 
biglycan.27,35-41 Notably, kidney intrinsic cells express components of NLRP3 
inflammasome pathway,42 and activation of this signaling can contribute to 
kidney injury.13,28 However, it is uncertain how NLRP3 is activated in these cells. 
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In this study, I particularly focused on regulators of mitochondrial biogenesis 
because dysregulated mitochondria can trigger the activation of NLRP3 
inflammasome pathway.43,44 
PGC-1α is a key regulator of mitochondrial biogenesis and plays an important 
role in mitochondrial dynamics and mitophagy.45-47 Given the relative abundance 
of mitochondria found in the kidney compared with other organs, growing 
attention has been paid to PGC-1α in kidney disease research field. In the kidney, 
PGC-1α expression is localized to the cortex and outer medulla, corresponding 
with regions of high mitochondrial activity.48 As damaged mitochondria are 
apparently observed in various forms of acute kidney injury (AKI), several 
studies have demonstrated the crucial protective role of PGC-1α against AKI.48 
Furthermore, there has been accumulating evidence that loss of PGC-1α 
contributes to the development of renal fibrosis and subsequent CKD.9,49,50 
Portilla et al.51 indicated that PGC-1α plays a role in the regulation of fatty acid 
oxidation during cisplatin-induced AKI model. Furthermore, transcript levels of 
Ppargc1α were notably decreased in patients with CKD compared with 
controls.52 The mRNA expression of Ppargc1α was significantly reduced in 
models of UUO–, folic acid–and APOL1-induced kidney fibrosis models. Most 
recently, in Notch-induced kidney injury model, PGC-1α also protected tubule 
injury and ameliorated fibrosis.9 Here, I demonstrated the role of PGC-1α in 
preventing kidney injury in light of regulation of NLRP3 pathway. Direct or 
indirect overexpression of PGC-1α attenuated TGF-β1-induced cell damage as 
well as activation of NLRP3 inflammasome. These results were consistent with 
animal models such as adenine-diet and UUO models. In adenine-fed mice, 
treatment of PGC-1α activators decreased oligomerization of NLRP3-ASC 
inflammasome. Conversely, down-regulation of PGC-1α augmented TGF-β1-
induced the activation of NLRP3 inflammasome and cellular injury.  
To date, few studies have examined the relationship between PGC-1α and 
NLRP3. In a study by Diao et al.,53 severe burn injury induced endoplasmic 
46 
 
reticulum (ER) stress in hepatocytes, and in turn activated NLRP3 inflammasome. 
Interestingly, activation of hepatic NLRP3 inflammasome was in parallel with 
inhibition of PGC-1α. They further examined the upstream regulators of PGC-1α 
such as protein kinase A catalyst, AMP-activated protein kinase, and sirtuin-1, 
all of which were significantly decreased after burn injury. They suggested that 
lack of PGC-1α may play an important role in the metabolic derangement and 
contributes to the activation of NLRP3 inflammasome pathway. To my 
knowledge, this is the first study that clarified the relationship on PGC-
1α/NLRP3 axis in RTECs.  
In the present study, I demonstrated several mechanisms that PGC-1α regulates 
NLRP3 inflammasome pathway in the kidney. Mitochondria are the powerhouse 
of the cell, and they play an important role in cellular homeostasis.54 Because 
RTECs have high energy–demanding function, mitochondrial dysfunction and 
reduced energy supply have been described in patients and animal models of 
CKD.55 Dysfunctional mitochondria eventually imperil cell viability, leading to 
cell death and dedifferentiation.56,57 PGC-1α orchestrates mitochondrial 
biogenesis by interacting with estrogen-related receptor-α, peroxisome 
proliferator–activated receptors, and nuclear respiratory factors 1 and 2, thereby 
increasing mitochondrial mass and overall mitochondrial function.58-60 Given that 
PGC-1α plays a key role in regulating mitochondrial biogenesis and 
mitochondrial dynamics, it can be suggested that PGC-1α regulates NLRP3 
inflammasome pathway via modulating mitochondrial viability. As shown in my 
data, the expression levels of mitochondrial dynamic-related genes were 
dysregulated in TGF-β1-treated RTECs. These changes were restored by direct 
or indirect overexpression of PGC-1α, while down-regulation of PGC-1α 
aggravated this dysregulation. The structural improvement of TGF-β1-induced 
mitochondria damage by PGC-1α were also observed by MitoTracker staining. 
In addition, transmission electron microscopy showed that destruction of 
mitochondrial structure by adenine diet-induced or UUO-induced kidney injury 
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was also restored by PGC-1α activators. Finally, I showed the release of mtDNA 
to cytosol from mitochondrial fraction in TGF-β1-treated RTECs. This release of 
mtDNA was prevented by PGC-1α overexpression. These findings together 
suggest that dysregulated mitochondrial dynamics contribute to the activation of 
NLRP3 inflammasome and consequent renal tubulointerstitial inflammation and 
fibrosis.  
 PGC-1α also has critical roles in essential metabolic processes such as fatty acid 
oxidation, oxidative phosphorylation, and ROS detoxification.57,61,62 In addition, 
several NLRP3-activating stimuli are associated with ROS production.36 Thus, 
regulation of oxidative stress levels by PGC-1α can affect NLRP3 inflammasome 
activation. Recently, mitochondrial ROS production has been described to trigger 
activation of NLRP3 inflammasome during renal tubulointerstitial fibrosis. 
Zhuang et al.21 reported that mitochondria-derived oxidative stress had key role 
in mediating the albumin effect on mitochondrial dysfunction and subsequent 
renal tubular injury. Furthermore, NLRP3 inflammasome was activated in the 
kidney by albumin overload, which was entirely abolished by MnTBAP, a 
mitochondrial ROS scavenger. In line with these study, I showed that enhanced 
oxidative stress was associated with the activation of NLRP3 inflammasome 
pathway during kidney injury. This increased oxidative stress level was 
attenuated by direct or indirect or direct overexpression of PGC-1α, whereas 
augmented after down-regulation of PGC-1α. The reduction of oxidative stress 
levels by PGC-1α activators was also confirmed in two different animal models. 
Taken together, enhanced oxidative stress levels including mitochondrial ROS 
production by PGC-1α deficiency can result in the activation of NLRP3 
inflammasome and consequent renal tubulointerstitial inflammation and fibrosis. 
TNFAIP3 is known to be directly regulated by PGC-1α and it has a role in 
inactivating NLRP3 inflammasome pathway in inflammatory cells such as 
macrophage. Kang et al.63 showed that dysfunctional telomeres cause 
macrophage mitochondrial distress, metabolic imbalance, and hyperactivation of 
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the NLRP3 inflammasome. They identified the PGC-1α/TNFAIP3 axis as a 
mechanism responsible for the homeostatic role of the telomere, and the 
disturbance of this axis led to inflammatory Terc-/- macrophages and severe 
bacterial pneumonia in Terc-/- mice. In the present study, TGF-β1 decreased 
transcript level of Tnfaip3 in RTECs. PGC-1α restored these changes, whereas 
PGC-1α knock-down further decreased Tnfaip3 level. Thus, PGC-1α /TNFAIP3 
axis is involved in regulation of NLRP3 inflammasome pathway in RTECs.  
 This study has several limitations. I did not use PGC-1α knock-out animal model 
in the present study due to infeasibility of proper genetic mouse model, the 
association between PGC-1α, mitochondrial biogenesis, and NLRP3 
inflammasome could not be clearly demonstrated in vivo. However, I thoroughly 
evaluated this relationship in vitro using various methods including the use of 
PGC-1α activators, and delivery or knockdown of PGC-1α. Second, kidney tissue 
obtained from animal models included both cortex and medulla. Thus, the renal 
tubule cell-specific effects of PGC-1α on mitochondria, and NLRP3 
inflammasome were not clear. In addition, possible involvement of other type of 
cells such as macrophage in kidney injury, which play an important role in 
activating NLRP3 inflammasome pathway, was not studied. However, RTECs 
constitutes 90% of the whole kidney and tubular cell death can trigger subsequent 
kidney injury. Thus, identifying the relationship between PGC-1α and NLRP3 in 
these cells is meaningful. Finally, metformin, which is known as PGC-1α 
activator, may have opposite effect on mitochondrial viability. Metformin 
modifies the production of ROSs and affects cell death processes, especially in 
cancer cells, which it has been also implicated in anti-neoplastic therapy.64 Most 
of these effects are caused by inhibiting complex 1 of mitochondrial respiratory 
chain.65 However, metformin is less toxic in non-cancer cells and it is possible 
that biologic effects of metformin differ between cancer and non-cancer cells. 
Future studies are warranted to uncover the direct effect of PGC-1α and its 






In the present study, I demonstrated the role of PGC-1α in the regulation of the 
NLRP3 inflammasome activation via modulating mitochondrial dynamics and 
viability, and TNFIP3 during kidney injury. These results suggest that inhibition 
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ABSTRACT (IN KOREAN) 
PGC-1α의 미토콘드리아 기능 및 NLRP3 inflammasome 활성화 
조절을 통한 신장 세뇨관-간질 섬유화 억제 효과  
 
< 지도교수 한 승 혁 > 
 
연세대학교 대학원 의학과 
 
지 종 현 
 
배경: NOD-like receptor, pyrin domain containing protein 3 (NLRP3) 
는 신장 질환에서 염증 반응, 세포사멸, 신섬유화에 기여하는 것으로 
알려져 있다. NLRP3 인플라마좀 (inflammasome)은 미토콘드리아 
손상에 의해 활성화 되나, 미토콘드리아의 활성 조절에 필수적인 
peroxisomal proliferator-γ coactivator-1α (PGC-1α)가 NLRP3 
인플라마좀 활성화에 기여하는 역할에 대해서는 밝혀진 바 없다. 
 
목적: 본 연구에서는 신섬유화 과정에서 PGC-1α가 미토콘드리아의 
구조 및 활성 조절을 통하여 NLRP3 인플라마좀의 활성화에 미치는 
영향을 알아보고자 하였다. 
 
방법: C57BL/6 쥐로부터 일차 세포 배양을 통해 얻은 신세뇨관 상피 
세포에 48시간동안 TGF-β1을 투여하여 신섬유화를 유발시킨 후 
PGC-1α를 간접적 혹은 직접적으로 과발현, siRNA를 처리하여 그 
발현을 저하시켜, NLRP3 인플라마좀, 미토콘드리아 형태 및 활성, 
신섬유화 및 세포 사멸 관련 인자들의 변화를 확인하였다. 동물 
실험으로는 C57BL/6 쥐에 아데닌 (adenine) 사료를 4주간 먹인 
모델과 일측성 요관 폐쇄를 시행한 신장 질환 모델에서 PGC-1α 
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활성화 약물을 투약 후, NLRP3 인플라마좀, 미토콘드리아 형태 및 
활성, 신섬유화 및 세포 사멸 관련 인자들의 변화를 확인하였다. 
 
결과: TGF-β1을 투여한 신세뇨관 상피 세포에서 PGC-1α 및 
미토콘드리아의 형태 관련 인자들의 발현이 감소하고, NLRP3 
인플라마좀과 섬유화, 세포 사멸에 관련한 인자들의 발현은 증가하는 
것을 확인하였다. 반면, PGC-1α 간접 혹은 직접적인 과발현 시 
미토콘드리아의 손상은 회복되고 활성산소종은 감소하며, tumor 
necrosis factor α induced protein 3 (TNFAIP3)의 발현이 증가하고, 
NLRP3 인플라마좀 및 섬유화, 세포 사멸 인자들의 발현은 감소하는 
것을 확인하였다. siRNA로 PGC-1α의 발현을 저하시킨 경우, 그 
반대의 결과들을 관찰하였다. 아데닌 사료 투여 및 일측성 요관 폐쇄 
동물 모델에서도 PGC-1α 활성화 약물 투약 시 미토콘드리아의 
손상은 회복되었고, 산화 스트레스의 감소 및 TNFAIP3 발현의 
증가를 관찰 할 수 있었으며, NLRP3 인플라마좀 및 섬유화, 세포 
사멸 인자들의 발현이 감소하는 것을 확인하였다.  
 
결론: 이상의 결과를 종합하여 볼 때, 신섬유화 과정에서 PGC-1α에 
의한 미토콘드리아 기능의 회복 및 활성산소종의 억제, TNFAIP3 
발현의 증가는 NLRP3 인플라마좀의 활성을 억제하여 신손상을 
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